Last updated on April 24, 2014 at 1:21 EDT

Latest blood-based cancers Stories

2012-12-06 16:23:38

SEATTLE, Dec. 6, 2012 /PRNewswire/ -- Adaptive Biotechnologies, a leading provider of next-generation sequencing assays for the adaptive immune system, today introduced clonoSEQ, a clinical assay to measure minimal residual disease (MRD) in a range of blood-based cancers that is significantly more sensitive than today's most common tests. clonoSEQ will be available for widespread clinical use by mid-2013. "This new approach of using high throughput sequencing to detect and track...